申请人:Astellas Pharma Inc.
公开号:US09051339B2
公开(公告)日:2015-06-09
A sulfur-containing bicyclic compound having a PAM action of GABAB, and it use for preventing and/or treating schizophrenia, CIAS, cognitive impairment, fragile X syndrome, autism spectrum disorder, spasticity, anxiety disorder, substance addiction, pain, fibromyalgia, or Charcot-Marie-Tooth disease. A pharmaceutical composition for preventing and/or treating schizophrenia, cognitive impairment associated with schizophrenia (CIAS), cognitive impairment, fragile X syndrome, autism spectrum disorder, spasticity, anxiety disorder, substance addiction, pain, fibromyalgia, Charcot-Marie-Tooth disease, or the like, which has a positive allosteric modulator (PAM action) of GABAB.
一种含硫的双环化合物,具有GABAB的PAM作用,并用于预防和/或治疗精神分裂症、CIAS、认知障碍、脆性X综合症、自闭症谱系障碍、痉挛、焦虑症、物质成瘾、疼痛、纤维肌痛或Charcot-Marie-Tooth病。一种药物组合物,用于预防和/或治疗精神分裂症、与精神分裂症相关的认知障碍(CIAS)、认知障碍、脆性X综合症、自闭症谱系障碍、痉挛、焦虑症、物质成瘾、疼痛、纤维肌痛、Charcot-Marie-Tooth病或类似疾病,其具有GABAB的正向变构调节剂(PAM作用)。